• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News

Our short URL is biophar.ma

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

coronavirus

Covovax/Nuvaxovid: Nanoparticle Vaccine for COVID-19
Posted inCOVID-19, Infections, New Drugs, Regulatory

Covovax/Nuvaxovid: Nanoparticle Vaccine for COVID-19

July 14, 2022August 4, 2022

Covovax/Nuvaxovid by Novavax is a protein subunit vaccine from virus-like particles.

Evusheld: First Drug for Strong and Long-Lasting Protection Against Coronavirus
Posted inCOVID-19, Infections, New Drugs, Regulatory

Evusheld: First Drug for Strong and Long-Lasting Protection Against Coronavirus

June 8, 2022August 4, 2022

One dose of AstraZeneca’s monoclonal antibody cocktail protects against COVID-19 for six months or longer.

Covifenz: Medicago’s Plant-Derived COVID-19 Vaccine
Posted inCOVID-19, Infections, New Drugs, Regulatory

Covifenz: Medicago’s Plant-Derived COVID-19 Vaccine

June 5, 2022August 4, 2022

Innovative Medicago’s vaccine is made by molecular pharming technology.

Xocova: Powerful New Japanese Pill for Coronavirus Treatment
Posted inClinical Trials, COVID-19, Infections

Xocova: Powerful New Japanese Pill for Coronavirus Treatment

April 25, 2022August 4, 2022

Ensitrelvir by Shionogi & Co. is a highly effective antiviral drug that works just as well as Pfizer’s Paxlovid.

proxalutamide
Posted inClinical Trials, COVID-19, Infections

Kropsen: Strong New Pill to Treat COVID-19 Infection

April 11, 2022August 4, 2022

Oral proxalutamide by Chinese Kintor Pharmaceutical effectively treats COVID-19 in outpatients and inpatients.

Posts navigation

1 2 3 … 6 Older posts
BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2022 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News